Novartis: presents benefits of Pluvicto

(CercleFinance.com) - Novartis' Pluvicto shows a statistically significant and clinically meaningful benefit in terms of progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC).


The Phase III study achieved the primary endpoint of progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) who were treated with an androgen receptor pathway inhibitor.

Pluvicto becomes the first radioligand therapy targeting PSMA to demonstrate clinical benefit in patients with mCRPC prior to taxane-based chemotherapy, addressing an important unmet need.

Results will be presented at an upcoming medical meeting and submitted to regulatory authorities for approval in 2023.


Copyright (c) 2022 CercleFinance.com. All rights reserved.